Nice post PJ and nice follow up question from WAG.
The concern for me is if the "above was completely predictable" then why is management trying to enter a P3 without a strategy. What, did they hope the FDA wouldn't notice the dose has been upped!!
Communication at an all time low with SP reflecting that. Lower than what I entered in some 8 years ago.
Bottom line is that this is actually a good thing... if we can enter a P3 with doses up to say 800 then we'll likely see stronger efficacy and at the same time shine a big spotlight on AD studies with potential correlation.
Nice post PJ and nice follow up question from WAG. The concern...
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $7.5K | 1.5M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 57 | 63305651 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 38258482 | 22 |
View Market Depth
| Last trade - 10.00am 12/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |